A compound of Formula (I) or a pharmaceutically acceptable salt, ester, prodrug, tautomer, stereoisomer, or hydrate, or solvate thereof: wherein a dashed line signifies that a single bond or a double bond can be present, provided that there are two double bonds and three single bonds in the ring comprising A 1 , A 2 , and A 3 ; A 1 , A 2 , and A 3 each independently is CH or S or N; provided that one of A 1 , A 2 , and A 3 is S; R 1 is di-substituted phenyl or di-substituted pyridinyl where the phenyl and pyridinyl substituents are each independently selected from the group consisting of halo, nitro, cyano, perfluromethyl, fluorinated methyl, and C 1-4 -alkoxy; provided that if R 1 is di-substituted phenyl, such phenyl is para-substituted with C 1-4 -alkoxy; R 2 is wherein a wavy line indicates a point of attachment; X is -NR'R"; R' is H, C 1-4 alkyl, n-hydroxy C 1-4 alkyl, -SO 2 -R 3 , or -CO-R 3 ; R" is -SO 2 -R 5 , C 1-4 alkyl substituted with 1 or more R 4 , or a ring moiety optionally substituted with R 6 wherein such ring moiety is pyridinyl, or oxazolyl; each R 3 is independently C 1-4 alkyl or H; each R 4 is independently a ring moiety optionally substituted with R 6 wherein such ring moiety is pyridinyl, or oxazolyl; each R 5 is C 1-4 alkyl substituted with 1 or more R 4 ; each R 6 is independently halo, OH, -NH 2 , -NHR 3 , -N(R 3 R 3 ), -COOH, - COOR 3 , -NHCO-R 3 , wherein the prodrug is selected from a prodrug modified hydroxyl group or amine group, and wherein: if the compound contains a hydroxyl group, the hydroxyl group is modified to form an acetate, pivalate, methyl or ethyl carbonates, or dimethylcarbamate or an ester derived from amino acids, or if the compound contains an amine group, the amine group is modified to form an acetamide or derivative with amino acids. a dashed line signifies that a single bond or a double bond can be present, provided that there are two double bonds and three single bonds in the ring comprising A 1 , A 2 , and A 3 ; A 1 , A 2 , and A 3 each independently is CH or S or N; provided that one of A 1 , A 2 , and A 3 is S; R 1 is di-substituted phenyl or di-substituted pyridinyl where the phenyl and pyridinyl substituents are each independently selected from the group consisting of halo, nitro, cyano, perfluromethyl, fluorinated methyl, and C 1-4 -alkoxy; provided that if R 1 is di-substituted phenyl, such phenyl is para-substituted with C 1-4 -alkoxy; R 2 is wherein a wavy line indicates a point of attachment; X is -NR'R"; R' is H, C 1-4 alkyl, n-hydroxy C 1-4 alkyl, -SO 2 -R 3 , or -CO-R 3 ; R" is -SO 2 -R 5 , C 1-4 alkyl substituted with 1 or more R 4 , or a ring moiety optionally substituted with R 6 wherein such ring moiety is pyridinyl, or oxazolyl; each R 3 is independently C 1-4 alkyl or H; each R 4 is independently a ring moiety optionally substituted with R 6 wherein such ring moiety is pyridinyl, or oxazolyl; each R 5 is C 1-4 alkyl substituted with 1 or more R 4 ; each R 6 is independently halo, OH, -NH 2 , -NHR 3 , -N(R 3 R 3 ), -COOH, - COOR 3 , -NHCO-R 3 , wherein the prodrug is selected from a prodrug modified hydroxyl group or amine group, and wherein: if the compound contains a hydroxyl group, the hydroxyl group is modified to form an acetate, pivalate, methyl or ethyl carbonates, or dimethylcarbamate or an ester derived from amino acids, or if the compound contains an amine group, the amine group is modified to form an acetamide or derivative with amino acids. <EOS>